Navigation Links
NIAID and Chinese officials sign agreement to foster TB research in China's Henan province
Date:4/28/2009

Officials from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and from China's Henan Provincial Bureau of Health will meet in Zhengzhou, China, on April 29 to sign an implementation arrangement intended to foster research on tuberculosis, including clinical research on new treatments for multidrug-resistant tuberculosis (MDR TB). The Henan Provincial Bureau of Health and the NIAID plan to develop jointly a collaborative TB research program at the Henan Provincial Chest Hospital.

"The emergence of drug-resistant strains of tuberculosis in China and elsewhere around the world is deeply concerning to public health officials everywhere," says NIAID Director Anthony S. Fauci, M.D. "The implementation arrangement is an important step toward what we expect will be a fruitful collaboration between U.S. and Chinese investigators. It also confirms our shared commitment to finding new ways to lessen the burden of tuberculosis."

NIAID Principal Deputy Director Hugh Auchincloss, M.D., will attend the signing ceremony. "The new initiative linking Chinese and U.S. investigators in the battle against TB is most welcome, especially in light of the recent call by the World Health Organization for expanded international research to combat this devastating disease," Dr. Auchincloss says.

According to the latest available figures from WHO, about 1.3 million people in China developed active TB disease in 2007. Researchers at the new center will carry out several projects, including clinical trials of new drugs or drug combinations designed to treat MDR TB and extensively drug-resistant TB (XDR TB). The WHO estimates that about 5 percent of newly diagnosed TB cases in China are multidrug-resistant, while 26 percent of previously but incompletely treated TB cases are multidrug-resistant. Drug-sensitive strains of TB usually can be treated successfully with a combination of antibiotics, but the lack of potent and affordable second-line TB drugs makes treating MDR and XDR TB extremely difficult. In addition to research leading to new MDR and XDR TB treatment approaches, the investigators also expect to work together to develop improved methods for rapid and accurate diagnosis of drug-sensitive and drug-resistant TB.


'/>"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID funds $51M contract to create comprehensive model of immune responses
2. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID to convene HIV Vaccine Summit
5. NIAID describes research priorities to fight drug-resistant tuberculosis
6. NIAID to advance B-cell approach to HIV vaccines
7. NIAID creates HIV vaccine discovery branch
8. NIAID awards contracts to search for protein markers of disease
9. NIAID media availability: Seizures following parasitic infection associated with brain swelling
10. NIAID honors AIDS activist Martin Delaney
11. High alcohol consumption increases stroke risk among Chinese men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
Breaking Medicine Technology: